Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Castration-resistant Prostate Cancer × pembrolizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 383 Melanoma 254 Squamous Cell Carcinoma of Head and Neck 191 Parkinson Disease 4, Autosomal Dominant Lewy Body 157 Neoplasms 150 Breast Neoplasms 136 Neoplasm Metastasis 129 Triple Negative Breast Neoplasms 127 Lung Neoplasms 123 Colorectal Neoplasms 120 Carcinoma, Renal Cell 110 Head and Neck Neoplasms 99 Ovarian Neoplasms 84 Stomach Neoplasms 80 Pancreatic Neoplasms 70 Carcinoma, Transitional Cell 70 Urinary Bladder Neoplasms 68 Carcinoma, Hepatocellular 60 Endometrial Neoplasms 57 Uterine Cervical Neoplasms 52 Esophageal Neoplasms 48 Recurrence 46 Prostatic Neoplasms 43 Glioblastoma 36 Carcinoma 36 Carcinoma, Squamous Cell 34 Sarcoma 32 Lymphoma 32 Hodgkin Disease 31 Brain Neoplasms 31

Interventions

enzalutamide 3 Radiotherapy 2 Metastasectomy 2 radium Ra 223 dichloride 1 pembrolizumab 1 disitamab vedotin 1 dactolisib 1 abiraterone 1 VT-464 1 Radiosurgery 1 NVP-BKM120 1 Ketoconazole 1 Hydrocortisone 1 Flutamide 1 Cyclophosphamide 1 Crizotinib 1 Control Groups 1 Carboplatin 1 Calcitriol 1 Blood Specimen Collection 1 Albumin-Bound Paclitaxel 1 Abiraterone Acetate 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03506997 2020-07-22

PERSEUS1

Institute of Cancer Research, United Kingdom

Phase 2 Unknown

Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡